Targeted drug delivery with liposome technology reduces IOP, maintains results

VANCOUVER, British Columbia — Subconjunctival injection of a liposome-latanoprost agent using nanotechnology reduced IOP in patients with glaucoma, and results were sustained through 3 months, a speaker said here.“Having sustained delivery is a ‘no-brainer.’ There’s more efficient drug use. There’s less drug wastage. The drug is independent of the patient’s compliance … You have targeted delivery of the drug to the right place, and you have round-the-clock delivery so you’re not worried about any loss of effect,” Tina T. Wong, FRCOphth, FRCSEd, PhD, said at the World Glaucoma Congress.

Full Story →